Technology


Overall Strategy: ABCDE-NK®
Our ABCDE-NK® Platform
  • <span>A</span>llogeneic <span>A</span>llogeneic
    Allogeneic
  • <span>B</span>lood-derived <span>B</span>lood-derived
    Blood-derived
  • <span>C</span>ryopreserved <br/>Off-The-Shelf <span>C</span>ryopreserved <br/>Off-The-Shelf
    Cryopreserved
    Off-The-Shelf
  • <span>D</span>esigned <br />On Demand <span>D</span>esigned <br />On Demand
    Designed
    On Demand
  • <span>E</span>xpanded <br/>to Clinical Scale <span>E</span>xpanded <br/>to Clinical Scale
    Expanded
    to Clinical Scale
ABCDE-NK® Strategy

Taking the unique advantages of NK cells in innate anti-tumor effect, our team develops a series of novel NK cell products based on our ABCDE-NK® platform and SynNK™ platform in order to maximize the therapeutic effect of NK cells (e.g. by enhancing targeting and infiltration, improving persistence, and resisting immune exhaustion), and provides first-in-class or best-in-class NK cell therapies to address the unmet clinical needs of patients with advanced tumor.

ABCDE-NK<sup>®</sup> Strategy

Telephone:021-50888199

Email: contact@nk-celltech.com

Our location:Building 7, Lane 100, Banxia Road, Zhoupu Town, Pudong New Area, Shanghai

WeChat

© Copyright by CSPC All rights reserved. ICP备字：沪ICP备2022013361号-1

Legal statement Privacy Policy Terms Of Use